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Summ a r y
The Wiskott–Aldrich syndrome (WAS) is an X-linked recessive primary immunode-
ficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. 
We treated two patients who had this disorder with a transfusion of autologous, 
genetically modified hematopoietic stem cells (HSC). We found sustained expres-
sion of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets 
after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were 
functionally corrected. After treatment, the patients’ clinical condition markedly 
improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and 
predisposition to severe infection. Comprehensive insertion-site analysis showed 
vector integration that targeted multiple genes controlling growth and immuno-
logic responses in a persistently polyclonal hematopoiesis. (Funded by Deutsche 
Forschungsgemeinschaft and others; German Clinical Trials Register number, 
DRKS00000330.)
T he Wiskott–Aldrich syndrome (WAS) is a complex primary immu-nodeficiency disorder that is characterized by recurrent infections, thrombo-cytopenia, eczema, and autoimmunity1,2 and caused by mutations in WAS.3 
Its gene product, WAS protein (WASP), is a key regulator of actin polymerization in 
he ma topoietic cells, with domains involved in signaling, cell locomotion, and immu-
nologic-synapse formation.4 The complex biologic features of this disease result 
from multiple dysfunctions in different subgroups of leukocytes, including defec-
tive function of T and B cells, disturbed formation of the NK-cell immunologic 
synapse, and impaired migratory responses in all leukocyte subgroups.4,5 Severe 
WAS leads to an early death from infection or bleeding.6 Currently, the only curative 
therapy consists of allogeneic HSC transplantation, which may be associated with 
considerable risk of death or complications related to transplantation.7
HSC gene therapy has emerged as an innovative therapeutic strategy for various 
primary immunodeficiency disorders.8-12 WAS is a promising candidate disease for 
gene-therapy approaches, since WASP expression is restricted to cells of the hemato-
poietic system, which grants a proliferative advantage over WASP-negative cells.13,14 
Preclinical studies have shown efficient reconstitution of cellular function in vitro 
and in vivo.13 On the basis of our own preclinical in vitro and in vivo studies,15,16 
we developed a clinical gene-transfer protocol.13 Here we report the results in two 
young boys who were treated with HSC gene therapy.
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Me thods
Study Design
The clinical gene-therapy protocol was reviewed 
by local and federal authorities, in accordance 
with current regulations of the European Com-
munity. Inclusion criteria for the study included 
an age of at least 12 months, a diagnosis of se-
vere WAS (as documented by molecular and 
clinical phenotype), no indication of malignant 
disease before gene therapy, documentation of in-
formed consent or informed assent, and isolation 
of a sufficient number of vital CD34+ cells from 
bone marrow or leukapheresis. Two 3-year-old 
boys who had been referred for gene therapy ful-
filled the inclusion criteria, and their parents 
provided written informed consent.
Study Oversight
The trial was conducted in compliance with the 
Good Clinical Practice guidelines of the European 
Clinical Trials Directive and the provisions of 
the Declaration of Helsinki. A detailed descrip-
tion of the technical methods that were used in 
the study is provided in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org.
R esult s
Patients
Patient 1 presented with hematoma and petechiae 
after birth, and within the first year of life, hemor-
rhagic colitis, eczema, and therapy-refractory 
autoimmune hemolytic anemia developed. In ad-
dition, he had autoimmune neutropenia and re-
current infections (bronchitis, otitis media, and 
enterocolitis). Molecular analysis revealed a splice 
site mutation in WAS, IVS6+1. No residual protein 
or somatic chimerism was detectable (Fig. 1 in the 
Supplementary Appendix).
Patient 2 presented with thrombocytopenia 
and hemorrhagic diathesis soon after birth. He 
had recurrent episodes of upper respiratory 
tract infection, life-threatening salmonella sep-
ticemia, and eczema that was not responsive to 
local and systemic therapy. Molecular studies 
revealed a known mutation in WAS (c. G257A, 
p. Arg86His).3,6 No residual protein or somatic 
chimerism was detectable (Fig. 1 in the Supple-
mentary Appendix).
Gene Transfer
We collected autologous CD34+ HSCs by leuka-
pheresis. The cells were then transduced with 
WASP-expressing retroviral vectors that were cre-
ated with backbone vector CMMP and pseudo-
typed with gibbon ape leukemia virus (GALV) en-
velope protein; the cells were then reinfused 4 days 
later (Table 1 in the Supplementary Appendix). 
Before reinfusion of CD34+ cells, busulfan was 
administered at a dose of 4 mg per kilogram of 
body weight per day on days 3 and 2 before the 
procedure. Transient myelosuppression and par-
tial alopecia were observed as therapy-associated 
side effects. For details regarding the vector that 
was used and the clinical gene-therapy protocol, 
see the Supplementary Appendix.
Restoration of WAS Expression
After gene therapy, WASP-positive cells in various 
leukocyte subgroups were detected on flow cytom-
etry (Fig. 1A and 1B). The frequency of WASP-
Figure 2 (facing page). Correction of Leukocyte Function 
after Gene Therapy (GT).
Formation of the immunologic synapse between natural 
killer (NK) cells and tumor cells (K562), which is impaired 
in patients with the Wiskott–Aldrich syndrome (WAS), 
is restored after GT. The localization of perforin is re-
stored 1 year after GT in Patient 2, with an immuno-
logic synapse similar in appearance to that in a sam- 
ple from a healthy control subject (HC) and in contrast 
to that from a patient with WAS who did not undergo 
GT (Panel A). Differential interference contrast (DIC) 
microscopy shows normal formation of cellular conju-
gates. However, an overlay view of the immunofluores-
cence analysis shows that the perforin staining is local-
ized close to the adjacent cells in a healthy control and 
in Patient 2 after therapy, in contrast to the findings in 
a patient with untreated WAS. NK-cell lytic activity is  
at least partially restored after GT in Patients 1 and 2, 
as compared with an untreated patient with WAS and  
a control subject (Panel B). Podosome formation is re-
stored in a fraction of monocytes from both patients 
after GT, as confirmed at multiple time points, in com-
parison with values in a control sample (Panel C). T-cell 
proliferative responses are normalized 2 years  after 
GT, after stimulation with phytohemagglutinin (PHA) 
or CD3, as compared with unstimulated (US) samples 
(Panel D). The skewed Vβ family repertoire for T-cell 
 receptors (TCRs), which was observed in both Patients 1 
and 2, has normalized after GT (Panel E). (For a com-
plete set of TCR Vβ spectratyping, see Fig. 9 in the Sup-
plementary Appendix.) The severe and therapy-refractory 
eczema in Patient 2 shows complete regression 2 years 
after GT (Panel F). The I bars indicate standard errors.
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positive monocytes, initially detected soon after 
gene therapy, has remained stable at 7 to 28%. 
An increased percentage of lymphoid cells were 
WASP-positive, consistent with a known prolifera-
tive advantage conferred by WASP expression in 
that lineage.14 The level of WASP-positive NK cells 
ranged from 25 to 90% over time. An increase in 
the percentage of WASP-positive CD4+ and CD8+ 
T cells was seen 6 to 12 months after gene ther-
apy and has remained stable ever since. Restora-
tion of WASP expression in peripheral-blood 
mononuclear cells was confirmed on Western 
blot analyses (Fig. 1C and 1D).
At the level of hematopoietic progenitor cells, 
a stable chimerism was found in the bone marrow 
of both patients, with 9% of CD34+ cells express-
ing the WASP transgene in Patient 1 and 20% in 
Patient 2 (Fig. 2 in the Supplementary Appendix). 
The presence of vector-positive cells in all leuko-
cyte subgroups at different time points after gene 
therapy was confirmed on quantitative poly-
merase-chain-reaction (PCR) assay (Fig. 3 in the 
Supplementary Appendix). PCR analysis of colony-
forming units from both patients confirmed vec-
tor integrations in 3 of 101 colonies in Patient 1 
and in 23 of 103 colonies in Patient 2 (data not 
shown).
An increase in platelet counts was noted, start-
ing 6 to 9 months after gene therapy, which 
marked the end of episodes of clinical bleeding 
(Fig. 1E and 1F). On the most recent follow-up, 
2.5 years after gene therapy, platelet counts were 
256,000 for Patient 1 and 88,000 for Patient 2. 
WASP expression in platelet-rich plasma from 
both patients was confirmed on Western blot and 
flow cytometric analysis (Fig. 1G and 1H, and 
Fig. 4 in the Supplementary Appendix).
Correction of Defective Leukocyte Function
We next analyzed whether restored WASP expres-
sion would lead to improved leukocyte function. 
In NK cells, WASP deficiency leads to a decreased 
accumulation of F-actin and perforin at the NK-
cell immunologic synapse,17 which reduces NK-
cell–mediated cytotoxicity. After gene therapy, 
substantial proportions of the NK-cell immuno-
logic synapses were restored in both patients 
(Fig. 2A, and Fig. 5 and 6 in the Supplementary 
Appendix), and NK-cell lytic activity was reconsti-
tuted (Fig. 2B). WASP-deficient monocytes and 
dendritic cells are characterized by the inability 
to form podosomes.4 The fraction of podosome-
positive monocytes after gene transfer ranged 
from 8 to 34% (Fig. 2C, and Fig. 7 in the Supple-
mentary Appendix), indicating that restored WASP 
expression reconstituted the capacity to rearrange 
the cytoskeleton in myeloid cells.
T-cell abnormalities in patients with WAS in-
clude diminished T-cell proliferative responses 
and a skewed antigen-recognition repertoire for 
T-cell receptors.4 After gene therapy, T-cell pro-
liferative responses were reconstituted at multi-
ple time points in both patients (Fig. 2D, and 
Fig. 8 in the Supplementary Appendix). Vβ gene 
spectratyping of T-cell receptors showed increas-
ing polyclonality of TCR usage in both patients 
after gene therapy, as shown by a distribution 
pattern that was consistent with decreasing oligo-
clonal T-cell receptor Vβ rearrangements (Fig. 2E, 
and Fig. 9 in the Supplementary Appendix).
The percentage of WASP-expressing B cells 
increased over time after gene therapy, with pro-
portions of WASP+CD19+ cells of 57% in Patient 
1 and 69% in Patient 2 2.5 years after gene ther-
apy. Abnormal immunoglobulin levels (increased 
IgM in Patient 1 and decreased IgG in Patient 2) 
normalized after gene therapy. Although normal 
immunoglobulin levels have remained stable in 
Patient 2, IgG levels have not remained at a pro-
tective level in Patient 1, who had undergone 
earlier splenectomy (Table 2 in the Supplemen-
tary Appendix). Both patients were immunized 
Figure 3 (facing page). Sustained Polyclonal Hemato-
poietic Repopulation after Gene Therapy.
In Panels A and B, retroviral insertion sites (RISs) were 
detected by linear-amplification–mediated polymerase-
chain-reaction (LAM-PCR) analysis of transduced hema-
topoietic cells at various days after gene therapy from 
bone marrow cells and primary blood leukocytes ob-
tained from Patients 1 and 2. CD3 denotes T cells,  
G granulocytes, HC healthy control subject, IC internal 
vector control, and M 100-bp marker. In Panels C and 
D, the relative contribution of individual clones re-
trieved from bone marrow cells and primary blood leuko-
cytes is estimated in sequenced polyclonal-cell samples 
from Patients 1 and 2. The presence of individual gene-
corrected cells is given as the percentage of all LAM-PCR 
amplicon sequence reads identified in a particular sam-
ple. The 10 most frequently sequenced RISs are ranked 
from 1 to 10 according to retrieval frequency. Genes 
that are highlighted in gray carry a RIS that was detected 
at more than one time point within the 10 most frequent-
ly sequenced sites. Also listed are the numbers of other 
unique, mappable RISs that were sequenced less fre-
quently than the first 10 in the respective sample ana-
lyzed, which are labeled “others.”
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with hexavalent vaccine 12 months after gene 
therapy and successfully produced specific anti-
bodies to tetanus, diphtheria, and Haemophilus in-
f luenzae (Table 3 in the Supplementary Appendix).
Infections and Autoimmunity
After gene therapy, the frequency and severity of 
infections decreased in both patients. However, 
2 years after gene therapy, Patient 1 had an epi-
sode of pneumococcal meningitis, which was re-
sponsive to intravenous antibiotic treatment. Con-
tributing factors may have been his previous 
splenectomy or insufficient B-cell reconstitution.
 Signs and symptoms of autoimmunity disap-
peared in both patients within the first year after 
gene therapy. In Patient 1, severe autoimmune 
hemolytic anemia (with polyspecific anti-Jka anti-
bodies), autoimmune thrombocytopenia (with 
antibodies directed against membrane glycopro-
teins IIb/IIIa, Ib/IX, and V), and autoimmune 
neutropenia (with antibodies against HNA-1a) 
disappeared (Table 4 in the Supplementary Ap-
pendix), and severe eczema resolved in Patient 2 
(Fig. 2F). Since recent studies have highlighted the 
role of regulatory T cells (Tregs) in controlling 
auto immunity in WASP deficiency,18 we measured 
the relative proportion of WASP-expressing regula-
tory T cells. The percentage of WASP-positive cells 
in CD4+CD25+FOXP3+ cells was higher than in 
the nonregulatory T-cell population (CD4+CD25−
FOXP3−) in both patients (Fig. 11 in the Supple-
mentary Appendix).
High-Resolution Analysis of Insertion Site
No morphologic or cytogenetic aberrations were 
seen in bone marrow aspirates after gene therapy. 
The clonal distribution and fate of gene-corrected 
cells in vivo were monitored by large-scale analy-
ses of retroviral vector insertion sites with linear-
amplification–mediated PCR (LAM-PCR),19 fol-
lowed by 454 pyrosequencing. In both patients, a 
highly polyclonal reconstitution pattern was seen 
in bone marrow cells, primary blood leukocytes, 
lymph-node cells (analyzed in Patient 1), sorted 
lymphoid CD3+ T cells, and myeloid granulo-
cytes (Fig. 3A and 3B). Of approximately 400,000 
raw LAM-PCR amplicon sequence reads, 5709 
unique retroviral insertion sites (in Patient 1) and 
9538 sites (in Patient 2) were retrieved from bone 
marrow, lymph nodes, and primary blood leuko-
cytes and could be mapped to a single position in 
the human genome. Vector integration occurred 
preferentially in the vicinity of transcription start 
sites and into gene coding regions of the human 
genome, reflecting a typical gammaretroviral 
target-site distribution (Fig. 12 in the Supplemen-
tary Appendix).
The abundance of individual gene-corrected 
cells and their clonal progeny in the hemato-
poietic system was estimated by the retrieval 
frequency of individual retroviral insertion site 
sequences generated by deep sequencing (Fig. 3C 
and 3D). In both patients, several clones appeared 
repeatedly within the 10 most abundant clones 
in each analyzed time point, indicating that 
clonal skewing had emerged among active hema-
topoietic gene-corrected clones. Ingenuity path-
way analyses in both patients revealed a sub-
stantial enrichment of genes that are involved in 
biologic processes regulating cellular develop-
ment, growth, and proliferation, as well as hema-
topoiesis. More specifically, a substantial en-
richment of vector insertions in or near genes 
regulating immune and autoimmune responses 
was observed in both patients (Fig. 13 in the 
Supplementary Appendix).
We further monitored the genomic distribu-
tion of insertion sites that were clustered in sub-
genomic regions and associated with particular 
reference sequence (RefSeq) genes over time as 
an indicator of in vivo selection of gene-corrected 
cells. In both patients, the same multiple vector 
targeted genes that were previously found to 
expand clones in gene-corrected myelopoiesis 
(MDS1/EVI1, PRDM16, and SETBP1) and lympho-
poiesis (LMO2, CCND2, and BMI1) were noted12,20-23 
(Fig. 3E and 3F). The most active cell clone in 
Patient 1 showed a vector integrant upstream of 
CCND2, and in Patient 2, the site of insertion was 
MDS1/EVI1 (Fig. 4A and 4B, and Table 5 in the 
Supplementary Appendix).
Insertion-site analyses in sorted CD3+ lympho-
cytes and myeloid granulocytes revealed that the 
clonal contribution of cells with insertions in co-
incident insertion sites that have been found to 
trigger clonal expansion in gene-corrected lym-
phopoiesis and myelopoiesis was almost exclu-
sively related to either lymphoid cells or myeloid 
cells (Fig. 4C and 4D). In contrast, retroviral in-
sertion sites that were identical between sorted 
lymphoid or myeloid cell fractions were also re-
trieved from both patients, at least 9000 times as 
frequently as expected by statistical chance alone. 
This marking indicates the initial transduction of 
cells with multilineage capacity (Table 6 in the 
Supplementary Appendix). Prospective monitoring 
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The results of screening for the presence and clonal contribution of highly prominent common-insertion-site (CIS) clones are shown for 
Patient 1 (Panel A) and Patient 2 (Panel B). At every time point analyzed, sequence counts for all retroviral insertion sites (RISs) contrib-
uting to an individual CIS derived from bone marrow cells and primary blood leukocytes are clustered and relate to the total sequence 
count at the respective time point. To estimate the overall contribution, the relative sequence counts in all CIS clones are related to se-
quence counts of non–CIS-related genes. (An overview of CIS clones that were detected at more than one time point is provided in Ta-
ble 5 in the Supplementary Appendix.) CISs of second order are defined as integration sites detected in a window of 30 kb, those of third 
order in a window of 50 kb, and those of fourth order in a window of 100 kb. CIS clones of fifth and higher orders were further defined in 
a window of 200 kb. The sequence count is given as a proportion of total sequence counts in CIS genes, as compared with the total 
overall sequence count, showing the number of days after gene therapy (GT). The relative clonal contribution of vector-targeted gene 
loci that have been shown to induce malignant clonal expansion in gene-therapy studies involving patients with chronic granulomatous 
disease (CGD) and severe combined immunodeficiency with γc-chain defects (γc-SCID) is shown for Patient 1 (Panel C) and Patient 2 
(Panel D). In both patients, the presence of LMO2, CCND2, and BMI1 (which have been shown to trigger malignant transformation of 
CD3+ T cells in patients with γc-SCID) was almost exclusively restricted to CD3+ T cells. Accordingly, the presence of MDS1/EVI1, 
PRDM16, and SETBP1 (which have been shown to trigger myeloid clonal expansion in patients with CGD) was largely found in granulo-
cytes (G). Numbers in parentheses indicate the number of clones containing an insertion site within or close to the respective RefSeq 
gene. The label “Other” indicates the number of all less frequently encountered genetic locations that carry insertion sites in the respec-
tive sample analyzed. The MDS1 clone carries an integration site at the MDS1 locus at position 169071575 bp on chromosome 3, which 
substantially contributes to myeloid regeneration.
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for signs of clonal dominance in gene-corrected 
hematopoiesis will continue in both patients.
Discussion
Previous clinical studies of hematopoietic gene 
therapy have reported sustained or temporary 
correction of lymphocytes in patients with severe 
combined immunodeficiency or adrenoleukodys-
trophy8,9,24 and of myeloid cells in patients with 
chronic granulomatous disease or adrenoleuko-
dystrophy.12,24 Our study shows that gene therapy 
for the Wiskott–Aldrich syndrome is feasible and 
has not been associated with treatment-limiting 
adverse events up to 3 years after gene therapy. 
These findings indicate the successful correction 
of early hematopoietic progenitor or stem cells 
that contributed quantitatively to all cell lineages 
of blood. We also confirmed correction of plate-
lets on transplantation of retrovirus-transduced 
HSCs in humans.
In line with a proliferative advantage of WASP-
positive cells,14 our results show increasing propor-
tions of corrected lymphocytes over time. Since 
the reconstitution of the lymphoid system reaches 
a plateau, there continues to be homeostatic con-
trol. Engraftment of progenitor cells was stable, 
similar to the results achieved in a recent trial of 
lentivirus-based gene therapy for adrenoleuko-
dystrophy,24 in which a completely myeloablative 
conditioning regimen was used.
The pathophysiology of thrombocytopenia in 
WAS is complex and involves decreased produc-
tion of platelets and increased immune and non-
immune mechanisms of platelet destruction.25 
This study provides evidence that gene transfer 
can correct thrombocytopenia in humans, a ma-
jor cause of death and complications in patients 
with WAS.
The assessment of the clonal inventory in pa-
tients whose disease has been successfully cor-
rected uncovers vector influence on key regula-
tors of hematopoiesis. In addition, we observed 
preferential targeting of genes implicated in auto-
immunity control, suggesting an unexpected, 
disease-related gene targeting. Most interestingly, 
insertion-site recovery in sorted lymphoid and 
myeloid fractions provides novel molecular evi-
dence that the molecular signatures contributing 
to long-term production of hematologic cells are 
distinct in both cell lineages of WAS patients. 
These data suggest that distinctive mechanisms 
control selective proliferative advantage or differ-
entiation of myeloid and lymphoid cells.
Despite targeting potential oncogenes, no per-
sistent clonal imbalance has yet been observed. 
Deep sequencing revealed a fluctuating pattern 
of molecularly defined hematopoietic clones and 
evidence of initial transduction of HSCs with 
multilineage capacity, suggesting that hematopoi-
esis continues to follow a cyclic pattern. Clini-
cally, both patients had marked improvement in 
their susceptibility to infection, autoimmunity, 
and bleeding. Longer follow-up and in-depth 
analyses in additional patients are warranted in 
light of the considerable clinical benefit derived 
from genetic correction of this disease. Hemato-
poietic stem-cell gene transfer may achieve com-
plete immunologic correction without producing 
the toxic effects implicit in the concept of retro-
virus-based stem-cell gene transfer.
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